Member Info for Saxondale

Hopefully publications like this will help raise Farons profile even further , showcasing the power of Bexmarilimab.
Its the Heineken of therapies ( refreshes the parts other therapies can't reach ) . You'd have to have been around in the seventies to get that reference .

https://www.ema.europa.eu/en/news/insufficient-data-use-inhaled-corticosteroids-treat-covid-19

Yes Meelie , if you don't have your bags full yet , £1.65 is still a great entry point .
My daughters ISA has a £1.58 average . And back then we were a lot further away from any results .
Currently a £326 million Mcap
And now possibly just a matter of weeks away from a P3 data set that could make SNG001 one of the most sought after therapeutics since Covid began .
All they have to do is get some semblance of the P2 trial , and we are all going to be a lot richer , very quickly .
As of now , all evidence is pointing to that being the case .
That data will put us into the Big Pharma shopping basket at alot more than £326 mil .

Theres charts , and then theres P3 trial data and Big Pharma billion $ deals.
Have to make do with the charts for now .
Enjoying this ride back up , looking very good :-)
Potent indeed !!

Small addition to the Clinical Trial . gov page for Bexmarilimab .
Date 24th May 2021
New trial site - Turku University Hospital - Recruiting .

That's a 5 minute walk from Faron HQ

Possibly added due to popular demand ?

I watched the Finnish presentation from yesterday .
Pretty much same as ours on Proactive .
He got some questions which i could translate , just general ones really , what the 5 yr plan was , when would drug be available etc , but the answers were all spoken in Finnish .
Interviewer was smiling throughout , so I guess the answers were positive lol .

Just a waiting game now

I kid you not that I had two guys I worked with , one called Dick Horn , and the other Dick Veryard . Neither saw the funny side of their names whatsoever , and preferred to be called Richard .

Conference in early June too - ASCO 2021
Some info here on Farons work that I found connected to that meeting- authored by Dr Petri Bono : Modelling treatment benefit for bexmarilimab
https://meetinglibrary.asco.org/record/200405/abstract

Not Yet Lime , they normally pop up the day after , but seen nothing extra from any of the companies on that forum evening .
Looks like there is a recorded presentation going out today , but I have a feeling it will be in Finnish .
https://www.youtube.com/watch?v=7IPVy1T-lwk
Maybe one of our Nordic visitors could give it a watch .

We had a friend called Hugh Janus

University of Kansas Health System channel on YouTube have been discussing Activ2 , and the inclusion of SNG001.
Often drop little teasers into progress being made .

Yes , a four hour delay then a boom ( and it seems to be holding and rising again now)
Someone may have made a few phone calls to Kansas ?

Imagine the market reaction when an EUA is announced , or P3 trial data .
It will dwarf anything like this .
I'm holding for the end game , and I don't think it is going to be too far away .

Potent antiviral activity .
Just looked up definition of potent ..
1.having great power, influence, or effect.
2.(of a male) able to achieve an erection or to reach an orgasm.

The case for SNG001 just gets better and better lol

Faron know that if they can prove up the ability of Bex to maintain the suppression of the soluble clever 1 through more frequent dosing , then it will be a double game changer .
They are keeping their powder dry .
No options are off the table .
Still 100% wholly owned .
Exciting times .
Then add in all this activity in the background surrounding Traumakine , with expanded trial targets and collaborations , and the kind of legal arrangements being tidied up ( with patents) that suggest things may be starting to accelerate there .
It really does finally feel like Faron are getting close to a significant breakout .

Looking at this report , apparently quite a lot .
https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market

In 2020 , the Checkpoint inhibitor market was estimated to be worth $12.9 billion
By 2025 it is expected to be worth $45.4 billion

Increasing by 28% each year .
Rising prevalence of cancer globally , and the increased funding and Govt support towards developing new drugs are fueling the growth in the CI market .
So how much is a drug that looks to be the envy of all others . One ring to rule them all ?

The market for ARDS treatments is in a similar position - expected to grow rapidly over the next 5 years.
https://ksusentinel.com/2021/05/21/acute-respiratory-distress-syndrome-ards-market-2021-sales-revenue-and-industry-leaders-firststring-research-inc-histocell-s-l-serendex-pharmaceuticals-a-s-faron-pharmaceuticals-oy-si/

Faron listed here in the 10 most important companies within the ARDS market .
I couldn't stretch to the $3995 they wanted for the report , but the title suggests the expected growth of the market will be ' extraordinary' , double figure billions already .

No wonder Markku describes it as a 'blockbuster' novel therapy .

The core aim of Faron has been to develop therapies for hard to treat illnesses , that have the potential to be multi billion dollar earners .

No wonder he has never been able to pluck a figure out to pin a value on the drugs .

Like others have said , we are in position now where there is all to play for .
Patents in place
Manufacturing in Place
Clear roadmap for progressing both drugs to market.
Tier 1 connections with Govt Funding bodies , Institutions , Universities and Research bodies .
Funding - available from multiple sources now I feel . No begging bowl type of raise if it is to happen . More some type of Govt or institutional collaboration .
A BOD well placed to carry this out , all with impeccable credentials .
Large Pharma playing close attention.

Looking forward to watching this play out .

In auction I think , can't buy or sell

I wouldn't call £1.08 a spike lol .
I remember people jumping at the chance to buy under £2 not long ago .
It just takes one piece of news to turn this share 180 degrees

What a positive interview .
Sounding very confident , and very clear about where they are focusing their studies in the outpatient groups .
Very reassuring that they are able to target these breathless patients , unlike the P2 home trial in the UK .
If it is Activ2 that he is talking about , then things are boding extremely well.
The main thing is to get data on treating breathless patients .
It looks like that's what they are able to do . My fear was that Activ 2 was going to throw up more data from people who weren't breathless enough .
And I'm lovin that dudes radio voice !

Yes it was a good update .
Now that the Matins part of the trial is coming to an end , it is interesting to see Markku change the slides somewhat , to highlight the significance Clevegen could have in the cancer world .
I didn't realise for instance that in the world of checkpoint inhibitors , only about 13% of patients responded . Yet they are hailed as one of the biggest breakthroughs .
And there Faron is with one cohort showing 31% response rate , and with the dosing and frequency being upped , that may even increase more.
For most outside the clinical science realm , much of this might be just overlooked .

He had so much to say , he was starting to take on the character of one of those guys selling a food blender on QVC . After every slide he'd say ' But there More , That's not all '' .

And then old Traumakine gets a couple of quick slides , and he drops in a little side note that it can probably help with cancer too . Interesting link with Birmingham University too in 2022 - not seen that before ?